PubMed Health⌕ Search

Biomedical subjects

H Musha

Publications and source records attributed to H Musha.

64 records · Page 4Linked to original sources
PubMed1976

Marked delay in indocyanine green plasma clearance with a near-normal bromosulphophthalein retention test: a constitutional abnormality?

Five patients showing a normal to near-normal BSP test and a marked delay in ICG plasma clearance, and two families with clustering of the same abnormality, are described. Two had Gilbert's syndrome, one was convalescing from acute hepatitis, and the other two had no detectable liver abnormality. Measured indices of ICG metabolism indicated a marked reduction in the hepatic uptake, storage capacity, biliary transport maximum, and an increased reflux into plasma. Biochemical studies on the binding of ICG by plasma proteins failed to demonstrate any difference from normal controls. Thus, the primary defect seems to be in the transport of ICG by the hepatocyte. Although the relationship of the defect in ICG metabolism to other constitutional hyperbilirubinaemias is not clear, it is possible that the defect in these patients is a constitutional one involving some steps in the hepatic disposal of organic anions.

Adult↗
PubMed1976

Hepatic vascular anomalies in nonparasitic cysts of the liver.

Vascular abnormalities demonstrated by angiography in 3 patients with nonparasitic liver cyst are described. In two cases of polycystic liver, dilated and mutually anastomosing hepatic vein branches were seen around a cyst as opacified by hepatic venography, and in one case of solitary liver cyst, anastomoses between large portal branches and a right hepatic vein was demonstrated by celiac angiography. These vascular abnormalities most likely represent developmental malformation along with aberrant bile duct formation expressed in the form of cystic liver. To exclude the possibility of these changes being secondary to expansion of the cyst, an angiographic study of excised polycystic liver was carried out, and it was found that cyst enlargement produced displacement and thinning but no anastomosis of the intrahepatic blood vessels.

Angiography↗
PubMed1975

Demonstration of growing casts of hepatocellular carcinoma in the portal vein by celiac angiography: The thread and streaks sign.

In 9 of 112 patients with hepatocellular carcinoma (HCC) examined by selective celiac and hepatic arteriography, an unusual finding, the "thread and streaks" sign, was observed. It began to appear shortly after the start of injection and was most clearly seen at 3.0-3.5 seconds. Histopathologic and radiographic studies of excised livers have demonstrated that these thin streaks correspond to the blood spaces and vessels which run longitudinally in and around a tumor cast growing in a large branch and trunk of the portal vein.

Aged↗
PubMedDate not supplied

A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation.

Percutaneous transluminal coronary angioplasty (PTCA) is widely used to treat patients with ischemic heart disease, but the procedure involves a number of problems, including acute coronary occlusion and restenosis. Although stents have proved useful for preventing post-PTCA restenosis, especially elastic recoil during the acute phase, no method has yet been established to prevent restenosis caused by vascular smooth muscle cell proliferation in the late phase. Cilostazol selectively inhibits the 3'5'-cyclic-nucleotide phosphodiesterase (PDE) III (cyclic guanosine monophosphate-inhibited PDE) of the cyclic adenosine monophosphate PDE family; it also has antithrombotic and vasodilating effects, as well as an inhibitory effect on vascular smooth muscle cell proliferation through PDE III inhibition. From November 1995 to March 1997, the usefulness of cilostazol versus aspirin in preventing subacute thrombosis and restenosis was studied in 70 patients (55 men and 15 women; 82 total lesions) who had undergone successful elective Palmaz-Schatz stent implantation. Patients were randomly allocated to receive aspirin 81 mg/d (40 patients with 45 lesions) or cilostazol 200 mg/d (30 patients with 37 lesions) alone. There was no difference in patients or angiographic characteristics between these groups. No subacute thrombosis, acute complications (ie, death, emergent coronary artery bypass grafting, or hemorrhagic complications), or drug side effects were found in the cilostazol group. The minimal lumen diameter (mean +/- SD) at follow-up was 1.89 +/- 1.08 mm in the aspirin group (41 lesions, 5.63 +/- 1.74 months after stent implantation) and 2.34 +/- 0.74 mm in the cilostazol group (35 lesions, 5.14 +/- 1.91 months after stent implantation), revealing statistically significant dilatation in the cilostazol group. The restenosis rate was 26.8% in the aspirin group, compared with 8.6% in the cilostazol group; this difference was statistically significant. Administration of cilostazol alone after the implantation of intracoronary Palmaz-Schatz stents was useful for the prevention of subacute thrombosis and restenosis.

Angioplasty, Balloon, Coronary↗